IRD
Opus Genetics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$322.83M
P/E Ratio
—
EPS
$-1.31
Beta
0.55
52W High
$5.81
52W Low
$0.90
50-Day MA
$4.83
200-Day MA
$3.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.00
PEG Ratio
—
About Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies aimed at treating rare retinal diseases that compromise vision. By harnessing cutting-edge research and proprietary gene-editing technologies, Opus is committed to addressing pressing unmet medical needs and enhancing ocular health. With a strong pipeline complemented by ongoing clinical trials and strategic partnerships, the company is positioned to drive meaningful advancements in patient care, while simultaneously offering significant value creation opportunities for institutional investors seeking exposure in the innovative healthcare sector.
Fundamentals
| Revenue (TTM) | $11.98M |
| Gross Profit (TTM) | $-21.45M |
| EBITDA | $-42.98M |
| Operating Margin | -666.00% |
| Return on Equity | -7595.00% |
| Return on Assets | -46.80% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $-0.64 |
| Price-to-Book | 23.82 |
| Price-to-Sales (TTM) | 26.94 |
| EV/Revenue | 22.04 |
| EV/EBITDA | -2.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -50.60% |
| Shares Outstanding | $82.57M |
| Float | $56.68M |
| % Insiders | 11.22% |
| % Institutions | 55.81% |
Historical Volatility
HV 10-Day
105.30%
HV 20-Day
84.15%
HV 30-Day
73.04%
HV 60-Day
68.88%
HV Rank
72.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($10.47 target)
2
Strong Buy14
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026